about
Islet-intrinsic effects of CFTR mutationNovel Roles for Chloride Channels, Exchangers, and Regulators in Chronic Inflammatory Airway DiseasesAsparaginase treatment side-effects may be due to genes with homopolymeric Asn codons (Review-Hypothesis)Islet biology, the CDKN2A/B locus and type 2 diabetes risk.Evidence for a causal relationship between early exocrine pancreatic disease and cystic fibrosis-related diabetes: a Mendelian randomization studyDiabetes-related mortality in adults with cystic fibrosis. Role of genotype and sexLoss of Slc26a9 anion transporter alters intestinal electrolyte and HCO3(-) transport and reduces survival in CFTR-deficient miceCentroacinar Cells Are Progenitors That Contribute to Endocrine Pancreas Regeneration.Reverse Pathway Genetic Approach Identifies Epistasis in Autism Spectrum Disorders.Genetic dissection of diabetes: facing the giant.Role of CFTR in epithelial physiology.Genetic susceptibility to type 2 diabetes and obesity: follow-up of findings from genome-wide association studies.Disease-modifying genes and monogenic disorders: experience in cystic fibrosis.Cystic fibrosis genetics: from molecular understanding to clinical application.Endocrine Disorders in Cystic FibrosisGenetic, cell biological, and clinical interrogation of the CFTR mutation c.3700 A>G (p.Ile1234Val) informs strategies for future medical intervention.A systematic review of genetic syndromes with obesity.The Mechanistic Links between Insulin and Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Cl- Channel.Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics.Extracellular Cl(-) regulates human SO4 (2-)/anion exchanger SLC26A1 by altering pH sensitivity of anion transport.Structural abnormalities in islets from very young children with cystic fibrosis may contribute to cystic fibrosis-related diabetes.Understanding childhood diabetes mellitus: new pathophysiological aspects.Hyperglycemia in Young Children with Cystic Fibrosis.Recent Progress in CFTR Interactome Mapping and Its Importance for Cystic Fibrosis.Islet Interleukin-1β Immunoreactivity Is an Early Feature of Cystic Fibrosis That May Contribute to β-Cell Failure.Variceal Hemorrhage and Adverse Liver Outcomes in Patients With Cystic Fibrosis Cirrhosis.The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9.Cystic fibrosis-related diabetes is caused by islet loss and inflammation.Evolving Mechanistic Views and Emerging Therapeutic Strategies for Cystic Fibrosis-Related Diabetes.Testing Calibration of Cox Survival Models at Extremes of Event Risk.Recent advances in developing therapeutics for cystic fibrosisRole of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic FibrosisPhysiological and Pathophysiological Relevance of the Anion Transporter Slc26a9 in Multiple Organs
P2860
Q26749173-653AA814-8D4C-47B4-B442-7E1854934D2AQ26776407-9AA0BC7F-FECB-4EE5-A656-99DEA4D116CEQ26801165-E7CE76FF-FD3C-40C5-8EBA-B06C0F454EC2Q30251397-D73D3EA8-519E-4FF3-953B-045FC1A6D9A9Q33646755-7EBA9E52-2D05-412A-8985-289CC8BD47A2Q35140718-0CA5F62E-069D-4517-B4CF-E204F422E878Q35194928-667155DE-320C-41DE-BD44-706A9CCC109DQ36104680-D42D6410-1CB9-4894-A3C9-2D76CBAFEB46Q36246158-E721F69B-E8EE-4705-A1F5-0E45905D4317Q37193266-604A00C0-4F44-47D1-9344-C526F1EF075EQ37553595-BC821C3A-408E-4BE9-8C1A-66E3F3880879Q37639793-B116B20D-570D-47BF-91E5-17350914253CQ38233032-53C8C6CA-CC2E-45CD-A9E9-22494617ECD3Q38268916-AAE3DB1F-AA3D-496A-887B-706A45C8429AQ38911660-8CA7954C-EDAA-4D20-83CD-FB5623FE88DBQ39022011-B74FE666-6E99-4BE8-B53C-4275FFA40AE6Q39202448-8C9BB1C9-0378-4961-9118-50C8CF1D711FQ40094842-E3A819CA-984C-4E10-ABC9-F2C32655A977Q40341616-9E9A230E-7541-470F-9E2D-5FB866587F17Q42408760-E9B77B49-BA4A-40CF-B0B5-1F26C31AFB74Q47154527-9A2685AD-0D7D-4F58-80C2-3B297B6CB838Q48106932-21BE42C1-EDD0-4B39-92AF-4C8077C613ECQ48301569-A4A0CFDC-D6A5-4C1B-9CED-EA107FBAFF7FQ49284664-160E90F5-D1F1-4383-8E4D-FD8F19A93E8DQ50044142-9998ACC5-3426-4ECB-92F5-B09E6D46D82BQ50106250-D6279F12-8C20-4A8C-9945-474721BBCF7DQ51080366-107362C3-5B62-48CC-B9C5-B49FC38F5F95Q52579658-DE236E49-89EA-410E-B4D2-D21E40F56179Q52739000-18862CC6-738A-4379-9B52-AD4C9765FA35Q55032805-9F7EB87B-4232-4357-A5B7-A199C0FEBD3CQ57172314-CE82669D-97FA-4A32-9DE6-860B786A392AQ57486621-EF7048F5-89BE-4390-8726-B6F583E18630Q58697833-41D2B618-39BD-4328-B2C6-D372D1B0BB39
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 May 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Genetic modifiers of cystic fibrosis-related diabetes
@en
Genetic modifiers of cystic fibrosis-related diabetes.
@nl
type
label
Genetic modifiers of cystic fibrosis-related diabetes
@en
Genetic modifiers of cystic fibrosis-related diabetes.
@nl
prefLabel
Genetic modifiers of cystic fibrosis-related diabetes
@en
Genetic modifiers of cystic fibrosis-related diabetes.
@nl
P2093
P2860
P356
P1433
P1476
Genetic modifiers of cystic fibrosis-related diabetes
@en
P2093
Christopher Watson
Fred A Wright
Garry R Cutting
Jaclyn R Stonebraker
Johanna M Rommens
Kristin M Arcara
Lisa J Strug
Michael R Knowles
Mitchell L Drumm
P2860
P304
P356
10.2337/DB13-0510
P407
P577
2013-05-13T00:00:00Z